* age \< 18 years * refusal of informed consent * physician decision that involvement in the trial was not in the patient's best interest * patients with a medical indication for anticoagulation therapy at the time of inclusion (for example, diagnosis of venous thromboembolism, atrial fibrillation, mechanical valve prosthesis) * platelets \< 50,000 / mm3 * patients with contraindications to anticoagulation (active bleeding, liver failure, blood dyscrasia, or prohibitive hemorrhagic risk in the investigator's assessment) * active cancer (excluding non-melanoma skin cancer) defined as cancer, not in remission or requiring active chemotherapy or adjunctive therapies such as immunotherapy or radiotherapy. * use of strong inhibitors of cytochrome p450 (cyp) 3a4 and/or glycoprotein p (p-gp) (eg protease inhibitors, ketoconazole, itraconazole) and/or use of p-gp and strong inducers of cyp3a4 (how but not limiting rifampicin/rifampicin, rifabutin, rifapentine, phenytoin, phenobarbital, carbamazepine or st. john's wort) * creatinine clearance \<30 ml / min * pregnancy or breastfeeding * known hiv infection * presence of one of the following uncontrolled or unstable cardiovascular diseases: stroke, ecg confirmed acute ischemia or myocardial infarction, and/or clinically significant dysrhythmia

* age \< 18 years * refusal of informed consent * physician decision that involvement in the trial was not in the patient's best interest * patients with a medical indication for anticoagulation therapy at the time of inclusion (for example, diagnosis of venous thromboembolism, atrial fibrillation, mechanical valve prosthesis) * platelets \< 50,000 / mm3 * patients with contraindications to anticoagulation (active bleeding, liver failure, blood dyscrasia, or prohibitive hemorrhagic risk in the investigator's assessment) * active cancer (excluding non-melanoma skin cancer) defined as cancer, not in remission or requiring active chemotherapy or adjunctive therapies such as immunotherapy or radiotherapy. * use of strong inhibitors of cytochrome p450 (cyp) 3a4 and/or glycoprotein p (p-gp) (eg protease inhibitors, ketoconazole, itraconazole) and/or use of p-gp and strong inducers of cyp3a4 (how but not limiting rifampicin/rifampicin, rifabutin, rifapentine, phenytoin, phenobarbital, carbamazepine or st. john's wort) * creatinine clearance \<30 ml / min * pregnancy or breastfeeding * known hiv infection * presence of one of the following uncontrolled or unstable cardiovascular diseases: stroke, ecg confirmed acute ischemia or myocardial infarction, and/or clinically significant dysrhythmia

- age < 18 years - refusal of informed consent - physician decision that involvement in the trial was not in the patient's best interest - patients with a medical indication for anticoagulation therapy at the time of inclusion (for example, diagnosis of venous thromboembolism, atrial fibrillation, mechanical valve prosthesis) - platelets < 50,000 / mm3 - patients with contraindications to anticoagulation (active bleeding, liver failure, blood dyscrasia, or prohibitive hemorrhagic risk in the investigator's assessment) - active cancer (excluding non-melanoma skin cancer) defined as cancer, not in remission or requiring active chemotherapy or adjunctive therapies such as immunotherapy or radiotherapy. - use of strong inhibitors of cytochrome p450 (cyp) 3a4 and/or glycoprotein p (p-gp) (eg protease inhibitors, ketoconazole, itraconazole) and/or use of p-gp and strong inducers of cyp3a4 (how but not limiting rifampicin/rifampicin, rifabutin, rifapentine, phenytoin, phenobarbital, carbamazepine or st. john's wort) - creatinine clearance <30 ml / min - pregnancy or breastfeeding - known hiv infection - presence of one of the following uncontrolled or unstable cardiovascular diseases: stroke, ecg confirmed acute ischemia or myocardial infarction, and/or clinically significant dysrhythmia

- age < 18 years - refusal of informed consent - physician decision that involvement in the trial was not in the patient's best interest - patients with a medical indication for anticoagulation therapy at the time of inclusion (for example, diagnosis of venous thromboembolism, atrial fibrillation, mechanical valve prosthesis) - platelets < 50,000 / mm3 - patients with contraindications to anticoagulation (active bleeding, liver failure, blood dyscrasia, or prohibitive hemorrhagic risk in the investigator's assessment) - active cancer (excluding non-melanoma skin cancer) defined as cancer, not in remission or requiring active chemotherapy or adjunctive therapies such as immunotherapy or radiotherapy. - use of strong inhibitors of cytochrome p450 (cyp) 3a4 and/or glycoprotein p (p-gp) (eg protease inhibitors, ketoconazole, itraconazole) and/or use of p-gp and strong inducers of cyp3a4 (how but not limiting rifampicin/rifampicin, rifabutin, rifapentine, phenytoin, phenobarbital, carbamazepine or st. john's wort) - creatinine clearance <30 ml / min - pregnancy or breastfeeding - known hiv infection - presence of one of the following uncontrolled or unstable cardiovascular diseases: stroke, ecg confirmed acute ischemia or myocardial infarction, and/or clinically significant dysrhythmia